China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine

Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's CSPCY messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization.
CSPC's mRNA became China's first domestically developed mRNA shot as COVID cases decline across the country after a resurgence, Reuters reports.
CSPS said its vaccine trials demonstrated incidents of adverse effects were substantially lower in an elderly group than an adult group.
CSPS said its independently developed mRNA vaccine SYS6006 targets some major Omicron variants. Its booster dose exhibited a good neutralization effect against Omicron subvariants BA.5, BF.7, BQ.1.1., XBB.1.5, and CH.1.1. in clinical trials.
CSPC has built a manufacturing practice-compliant production plant for the vaccine. CSPC also produces critical raw materials and excipients.
The vaccine could be stored at 2-8 degrees Celsius for a long time.
In a study of 4,000 participants from December 10 - January 18, when China was going through a surge in infections, the vaccine showed an efficacy of 85.3%, 14 to 28 days after booster vaccination.
CSPC also reported an 8.7% growth in 2022 net profit on Wednesday, backed by several newly launched generic drugs in China's national drug procurement program.
China has declined to use global mRNA vaccines, and China's vaccines were deemed less effective than the Moderna, Inc MRNA and Pfizer, Inc PFE-BioNTech SE BNTX mRNA shots.
Price Action: MRNA shares traded higher by 0.85% at $153.39 on the last check Wednesday.
Image by Spencer Davis from Pixabay

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga